{
    "symbol": "ZLAB",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-11 15:08:12",
    "content": " I am pleased to say we continue to progress toward achieving these priorities, including progress toward filing the NDA for efgartigimod in China in mid-2022, initiation of a registrational study for bemarituzumab in first-line gastric cancer in Greater China, top line data readout for KarXT from its Phase 3 EMERGENT-2 trial by third quarter 2022, and continued investment in R&D to advance our proprietary pipeline with global rights, including moving ZL-1102 into full global development."
}